Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome

Cardiometabolic Syndrome Clinical Trial

Official title:
Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome Based on NCEP-ATP III Criteria With Modification on Obesity Classification (Waist Circumference Measurement) for Asian Population

Status Enrolling by invitation

Clinical Trial Summary

The aim of this study is to determine the role and efficacy of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) from mycelia extract of Indonesia's Ganoderma lucidum as an antioxidant and anti-inflammatory agent on cardiometabolic syndrome

Clinical Trial Description

This study is held at Saiful Anwar General Hospital and General Hospital of Brawijaya University by enrolled 70 participants and using a double-blinded true experimental using a randomized control perspective method with pre-test and post-test design, to determine the effect of giving β-1,3/1,6-D-Glucan (Polysaccharide Peptide) from mycelia extract of Indonesia's Ganoderma lucidum on cardiometabolic syndrome population. The intended target or experimental variables that will be studied in this study are blood pressure, body mass index, blood glucose profile (fasting glucose, HbA1C), lipid profile (total cholesterol, High-Density Lipoprotein, Low-Density Lipoprotein, and triglyceride), renal function profile (urea and creatinine), heart function from echocardiography examination, inflammation parameter (Interleukin 6, Tumor Necrosis Factor-Alpha, and high sensitivity C-Reactive Protein), stress oxidative parameter (superoxide dismutase and malondialdehyde), endothelial function parameter (nitric oxide), and quality of life that conducted by completion of the SF-36 questionnaire. Hypothesis of this study is β-1,3/1,6-D-Glucan (Polysaccharide Peptide) from mycelia extract of Indonesia's Ganoderma lucidum can acts as a chronic anti-inflammatory and antioxidant agent in cardiometabolic syndrome patients by contributing in blood pressure control, body mass index control, blood glucose improvement, lipid profile improvement, renal function profile improvement, heart function improvement, and better quality of life. Beside that, the investigators hope that there will be a change of inflammation, stress oxidative, and endothelial function parameter in which shift to the good level. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05079529
Study type	Interventional
Source	University of Brawijaya
Contact
Status	Enrolling by invitation
Phase	Phase 2
Start date	June 30, 2021
Completion date	January 6, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05880758` - Impact of Yo-Yo Sleep on Cardiometabolic Health	N/A
Active, not recruiting	`NCT05192590` - Establishing Clinical Utility Evidence for Chronic Disease Management Testing	N/A
Completed	`NCT06058845` - Efficacy of Tamarindus Indica Fruit Juice in Optimizing Cardiometabolic Health of Patients Living With HIV	N/A
Completed	`NCT05473026` - Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors	N/A
Enrolling by invitation	`NCT06284772` - FINRISK 2002 Re-examination
Completed	`NCT05071833` - Effects of Peppermint Oil in Cardiometabolic Outcomes	N/A
Active, not recruiting	`NCT05309057` - Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk
Recruiting	`NCT05897073` - Time-Restricted Eating, Exercise and Cardiometabolic Health in Obesity	N/A
Recruiting	`NCT06371937` - iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease
Recruiting	`NCT06003686` - Spinal Cord Injury Model Systems (SCIMS) - Education Module	N/A
Recruiting	`NCT05775016` - Effects of Adding L-BAIBA to Exercising Adult Overweight and Obese Men and Women	N/A
Recruiting	`NCT05350111` - CArdioMetabolic Prevention in Adolescents	N/A
Completed	`NCT06158191` - Long-term Benefits of Abdominal Fat Loss in Abdominally Obese Dyslipidemic Patients (SYNERGIE Study)	N/A
Recruiting	`NCT04801745` - Vegan Diet, Amla Fruits and Uric Acid	N/A
Not yet recruiting	`NCT06230861` - Effects of Quercetin on Cardiometabolic Outcomes	N/A
Active, not recruiting	`NCT05627570` - A Study Comparing the Health Effects of Two Diets Following UK Dietary Guidance in People Living With Overweight or Obesity	N/A
Active, not recruiting	`NCT04784624` - Virtual Lifestyle Program Evaluation During Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Completed	`NCT04776629` - A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors	Phase 2
Completed	`NCT06457711` - Blood Pressure and Cardiometabolic Risk (Diet-to-HTN)	N/A
Completed	`NCT06008886` - Effect of a Vegan Diet Versus a Mediterranean Diet. Assessing Health Outcomes	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.